As US measles cases rise, biotech firms start developing new treatments
At a glance
Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease. But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working
- Primary source
- Ars Technica - All content — Read original article
- Published
- Topic
- General
Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease.
But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection.
It will likely be years, however, before these countermeasures are available, and it’s even more uncertain if those who refuse vaccines would take such treatments.
Fueled by large outbreaks in South Carolina and Utah , the US had already surpassed last year’s 2,289 measles cases, and it’s only July. For comparison, there were just 285 cases in all of 2024.
Read full article Comments
This summary comes from Ars Technica - All content. Read the full article at the original source.